Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans.
about
Prodrugs of phosphonates and phosphates: crossing the membrane barrierSulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104AA phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumoursInitial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.Glucuronides from metabolites to medicines: a survey of the in vivo generation, chemical synthesis and properties of glucuronides.Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice.A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.
P2860
Q27005712-72A09526-DE1B-40EA-BBE6-91E227FDF596Q28550585-61C5172E-5939-4218-8EC6-BF6FE2CFBA47Q33397528-38D2087E-3259-42B6-B928-701B55AAA455Q33404024-5AB123DA-953E-4ADB-9955-EDC9C769D132Q35005290-B73903B3-2818-4168-81B0-36EDA15B56F0Q36212847-FA915673-6FF1-44BF-94BA-67F480E845D2Q37217739-0E92E165-B3BA-417E-A25B-0F3F0C4EFA15Q38104574-0C749452-E8BE-4B91-80FB-757E770563A0Q38177279-A8A86BE1-7D0A-4C0D-8C7F-A74313996033Q39703345-238A8ABA-8B94-4F2B-B989-C3C94756E548Q41370914-96DC73D6-3728-40B7-97B1-B3A26E6754D1Q44502775-7BC82786-B300-45E5-B1EE-E8BC77591C6E
P2860
Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Metabolism and excretion of th ...... mice, rats, dogs, and humans.
@en
Metabolism and excretion of th ...... mice, rats, dogs, and humans.
@nl
type
label
Metabolism and excretion of th ...... mice, rats, dogs, and humans.
@en
Metabolism and excretion of th ...... mice, rats, dogs, and humans.
@nl
prefLabel
Metabolism and excretion of th ...... mice, rats, dogs, and humans.
@en
Metabolism and excretion of th ...... mice, rats, dogs, and humans.
@nl
P2093
P356
P1476
Metabolism and excretion of th ...... mice, rats, dogs, and humans.
@en
P2093
Graham J Atwell
William R Wilson
Yongchuan Gu
P304
P356
10.1124/DMD.109.030973
P577
2009-12-17T00:00:00Z